Tags : Gilead Sciences

Top 20

Top 20 BioPharma Companies based on 2020 Total Revenue

Despite having the global Covid-19 pandemic, the biopharma companies were involved in multiple M&A and licensing deals. The major focus of the year remains the production and distribution of vaccines to combat the COVID-19 globally All of the Biopharma companies on our list are on the front line to combat this global crisis. The top […]Read More

Top 20

Top 20 Biopharma M&A of 2020 by Total Deal Value

Biopharma merger and acquisition activity in 2020 was mainly filled with late-stage, bolt-on acquisitions, which were orders of magnitude smaller than the mega M&A deals of prior years. AstraZeneca holds the top rank by acquiring Alexion Pharmaceuticals among the top 20 acquisitions with a total deal value of $39B at a 1-day premium of 45% […]Read More

M&A

Gilead to Acquire MYR for ~$1.4B

Shots: Gilead to acquire MYR for ~$1.4B in the all-cash transaction along with ~$364.73M as a milestone upon the US FDA’s approval of Hepcludex (bulevirtide) The acquisition will provide Gilead with Hepcludex which has received EMA’s conditional approval for chronic HDV infection in adults with compensated liver disease in Jul’2020. MYR anticipates the submission for […]Read More

Top 20

Top 20 Prescription Drugs Based on 2019 Revenue

The average life expectancy span of Human Beings are increased due to better medical facilities and drugs developed by Biopharma companies. Pharmaceutical products or drugs or medicines are being produced for a wide range of medical sectors. It includes the lifesaving drugs or the major therapy area including immunology, cardiology, and neurology but are they […]Read More

Biotech

Gilead Sciences and Second Genome Signs a Four-Year Collaboration to

Shots: Second Genome will receive $38M as upfront, up to $300M milestones for each of five target discovery programs and royalties for approved therapies. Additionally, it will receive milestones for each validated biomarker delivered under the collaboration The collaboration will deploy Second Genome’s Microbiome Analytics Platform to identify biomarkers associated with clinical response in up […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (August 12-16, 2019)

Profound Medical’s TULSA-PRO Receives the US FDA’s 510(k) Clearance for Ablation of Prostate Tissue Published: Aug 16, 2019 | Tags: 510(k), Ablation, Clearance, Profound Medical, Prostate Tissue, Receives, TULSA-PRO, The US FDA 2. Mallinckrodt Reports Positive Results of Terlipressin in P-III CONFIRM Study for Hepatorenal Syndrome Type 1 Published: Aug 16, 2019 | Tags: CONFIRM, Hepatorenal Syndrome […]Read More